AvevoRx Closes Sunrise Rx Deal, Expands Northeast Infusion Reach

The Catalyst: Closing on Sunrise Rx

AvevoRx, a private specialty infusion pharmacy provider, announced the close of its acquisition of Sunrise Rx, a Long Island-based operator serving New York, New Jersey, Connecticut, and New Hampshire. The deal gives AvevoRx a scalable platform in the Northeast, a region that accounts for a disproportionate share of biologic and gene-therapy patient volumes.

The acquisition closed without disclosed terms. Sunrise Rx founders Rich Collins and Dan Manchise will remain involved. Collins leads New York pharmacy operations; Manchise supports growth through a consulting agreement with Mann Medical Consultant Group.

What the Asset Brings

Sunrise Rx built relationships with regional payors and referral networks across four states. The source text describes those ties as